Amgen Completes Acquisition of Avidia
Advertisement
Amgen announced the completion of the acquisition of Avidia, a privately held biopharmaceutical company that discovers and develops a new class of human therapeutic known as Avimer(TM) proteins. The transaction provides Amgen with Avidia's lead product candidate, an inhibitor of interleukin 6 (IL-6) for the treatment of inflammation and autoimmune diseases, which is in Phase 1 clinical trials.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Biosynth Carbosynth, vivitide and Pepscan Rebrand to Biosynth - Rebranding aligns core Biosynth Group members across Complex Chemical and Peptide Manufacturing Services and Catalog Business

The farm effect: antiallergic properties of the cow’s milk protein BLG - The milk protein is also found in stable dust and ambient air: Together with its binding partners, BLG may contribute to the protection against asthma and allergies
